Changeflow GovPing Pharma & Drug Safety Monoclonal antibody matrix metalloproteinase-1 ...
Routine Notice Added Final

Monoclonal antibody matrix metalloproteinase-1 patent granted

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted Patent US12595315B2 to S&T BIOMED CO., LTD. for a monoclonal antibody specific to matrix metalloproteinase-1. The patent covers the antibody's heavy and light chain variable regions with specific CDR sequences, along with polynucleotides, detection kits, and detection methods. This grant date is April 7, 2026.

What changed

The USPTO granted Patent US12595315B2 to S&T BIOMED CO., LTD. covering a monoclonal antibody targeting matrix metalloproteinase-1 (MMP-1). The patent protects the antibody's heavy and light chain variable regions with defined CDR sequences, along with associated polynucleotides, detection kits, and detection methods.

For entities conducting MMP-1 related research or developing diagnostic applications, this patent grant establishes intellectual property protection that may require licensing or design-around strategies to avoid infringement during commercialization efforts.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Monoclonal antibody of matrix metalloproteinase-1, detection kit and detection method thereof

Grant US12595315B2 Kind: B2 Apr 07, 2026

Assignee

S&T BIOMED CO., LTD.

Inventors

Ya-Ting Chang, Jau-Song Yu, Jun-Sheng Wang, Shu-Fang Wu, Chih-Ju Chen, Yen-Chun Liu

Abstract

Provided is a monoclonal antibody of matrix metalloproteinase 1. The monoclonal antibody has a heavy chain variable region with an amino sequence comprising i) CDR1 selected from the group consisting of SEQ ID NOs: 1, 7 and 13, ii) CDR2 selected from the group consisting of SEQ ID NOs: 2, 8 and 14, and iii) CDR3 selected from the group consisting of SEQ ID NOs: 3, 9 and 15. The monoclonal antibody also has a light chain variable region with an amino sequence comprising i) CDR1 selected from the group consisting of SEQ ID NOs: 4, 10 and 16, ii) CDR2 selected from the group consisting of SEQ ID NOS: 5, 11 and 17, and iii) CDR3 selected from the group consisting of SEQ ID NOs: 6, 12 and 18. A polynucleotide, a detection kit and a detection method are also provided as well.

CPC Classifications

C07K 16/40 C07K 2317/565 G01N 33/54387

Filing Date

2020-02-27

Application No.

17791744

Claims

12

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12595315B2

Who this affects

Applies to
Pharmaceutical companies Medical device makers
Industry sector
3254.1 Biotechnology
Activity scope
Biopharmaceutical research Diagnostic kit development Antibody technology
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Medical Devices Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!